Circle Pharma initiated operations in June 2014 with seed funding from Pfizer, Inc. and Mission Bay Capital, LLP; we received additional seed funding from ShangPharma Investment Group Limited in November 2015. We design and develop bioavailable macrocyclic peptide therapeutics against important clinical targets. We do this by applying a computational structure-based design approach that combines physics (conformational modeling), chemistry (innovative molecular components) and biology (protein target structure and function). We have selected intracellular protein-protein interactions that play key roles in cancer as the initial target group for our internal pipeline development.
Circle is taking a new approach to the development of macrocylic peptide therapeutics that is based on the pioneering work of its founders to understand and computationally predict drug-like properties of macrocycles. Circle is advancing this understanding to design novel, inherently permeable macrocyclic peptide drug candidates against Circle’s internal targets and those of our collaboration partners.
Our workflow includes the use of proprietary algorithms to design large, conformationally diverse, virtual libraries of cell permeable macrocyclic scaffolds that incorporate natural and non-natural backbone components. We deploy these virtual scaffold libraries in subsequent design steps that include the incorporation of functional side chains selected for both target binding and maintenance of permeability. Candidate compounds are synthesized and tested for both permeability and target affinity and the results are used to inform subsequent design cycles.
Circle is taking a new approach to the development of macrocylic peptide therapeutics that is based on the pioneering work of its founders to understand and computationally predict drug-like properties of macrocycles. Circle is advancing this understanding to design novel, inherently permeable macrocyclic peptide drug candidates against Circle’s internal targets and those of our collaboration partners.
Our workflow includes the use of proprietary algorithms to design large, conformationally diverse, virtual libraries of cell permeable macrocyclic scaffolds that incorporate natural and non-natural backbone components. We deploy these virtual scaffold libraries in subsequent design steps that include the incorporation of functional side chains selected for both target binding and maintenance of permeability. Candidate compounds are synthesized and tested for both permeability and target affinity and the results are used to inform subsequent design cycles.
Location: United States, California, South San Francisco
Employees: 11-50
Total raised: $207.5M
Founded date: 2012
Investors 7
Funding Rounds 5
Date | Series | Amount | Investors |
12.09.2024 | Series D | $90M | - |
16.06.2021 | Series C | $66M | - |
17.03.2020 | Series B | $45M | - |
25.04.2017 | Series A | $2M | - |
21.12.2016 | Series A | $4.5M | - |
Mentions in press and media 40
Date | Title | Description |
12.09.2024 | Circle Pharma: $90 Million (Series D) Raised For Improving Oral Macrocycle Therapies | Circle Pharma, a clinical-stage biopharmaceutical company focused on discovering and developing cell-permeable macrocycles as a new class of therapies, announced the successful closing of a $90 million Series D financing round – which inclu... |
09.09.2024 | Circle Pharma Announces Preclinical Data Poster Presentation of CID-078, a First-and-Only-in-Class Cyclin A/B RxL Inhibitor at the 2024 World Conference on Lung Cancer | SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–September 9, 2024– Circle Pharma, a clinical-stage biopharmaceutical company dedicated to discovering and developing cell-permeable macrocycle therapies, today announced that it presented a digita... |
04.09.2024 | Circle Pharma Secures $90 Million to Propel Innovative Cancer Therapies | In the bustling heart of South San Francisco, Circle Pharma has struck gold. The clinical-stage biopharmaceutical company recently closed a $90 million Series D financing round. This infusion of capital is not just a financial boost; it’s a... |
03.09.2024 | Kyrrex: Your Digital Ecosystem For Secure and Convenient Cryptocurrency Management | The cryptocurrency market continues to evolve rapidly, opening up new opportunities for private and institutional investors. In this dynamic world, platforms that can offer safe, secure and convenient solutions are becoming key players in t... |
03.09.2024 | Circle Pharma Closes $90 Million Series D Financing to Advance Innovative Oral Macrocycle Therapies | SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–September 3, 2024– Circle Pharma, a clinical-stage biopharmaceutical company dedicated to discovering and developing cell-permeable macrocycles as a new class of therapies, today announced the suc... |
03.09.2024 | Circle Pharma Closes $90M Series D Financing | Circle Pharma, a San Francisco, CA-based clinical-stage biopharmaceutical company dedicated to discovering and developing cell-permeable macrocycles as a new class of therapies, raised $90M in Series D funding. The round was led by The Colu... |
01.07.2024 | Circle Pharma files first Investigational New Drug application for first-in-class oral cyclin A/B RxL inhibitor for treatment of advanced solid tumors | SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–July 1, 2024– Circle Pharma, a leader in macrocycle drug discovery and development, announced the submission of its first Investigational New Drug (IND) application to the U.S. Food and Drug Admin... |
19.04.2023 | Circle Pharma’s first-in-class orally bioavailable macrocyclic cyclin A/B inhibitors highlighted in poster presentations at American Association for Cancer Research Annual Meeting | Data show activity across a wide range of human tumor cell lines Tumor regression observed in xenograft models of small cell lung cancer and ovarian cancer Research from the laboratory of Dr. Matthew Oser at the Dana Farber Cancer Institute... |
15.12.2022 | Circle Pharma Appoints Stephen Kelsey, MB ChB, MD, to its Board of Directors | SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–December 15, 2022– Circle Pharma, a company focused on developing macrocycle therapeutics against targets previously considered to be undruggable, has appointed Stephen Kelsey as an independent me... |
26.07.2022 | Circle Pharma Appoints Paul Park, MBA, as its Chief Business Officer | SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–July 26, 2022– Circle Pharma, a company focused on developing macrocycle therapeutics against targets previously considered to be undruggable, has appointed Paul Park, MBA, as its Chief Business O... |
Show more